Featured
Search Clinical Trials
Not Yet Recruiting
Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV (External Link)
The UNIVERSAL2 study is a research project designed to evaluate a newly developed formulation of an approved drug for children living with HIV aged over 3 years and weighing between …
Baylor Role:
Collaborator
Not Yet Recruiting
ADELANTE: A Randomized Controlled Trial to Improve Engagement in Care for Latinos With HIV (External Link)
Participants will be Latinx/Hispanic individuals age ≥18 years who are at least 6 months since initiation of HIV treatment and have evidence of viral non-suppression (HIV RNA ≥200 cpm). Participants …
Baylor Role:
Collaborator
Not Yet Recruiting
UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children (External Link)
Dolutegravir (DTG), Emtricitabine (FTC) and Tenofovir alafenamide (TAF) are anti-HIV medicines. DTG works very well, can be taken once-daily and has few side effects. In international treatment guidelines, DTG is …
Baylor Role:
Collaborator
Recruiting
Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service (External Link)
Tuberculosis (TB) is the world's leading infectious cause of mortality and responsible for 1/3 of deaths in people living with human immunodeficiency virus (PLHIV). Children and adolescents living with HIV …
Baylor Role:
Lead Sponsor
Recruiting
Midwest TXTXT Scale up of an Evidence-Based Intervention to Promote HIV Medication Adherence (External Link)
In this study investigators propose to use implementation science (IS) to scale up and evaluate the TXTXT evidence-based intervention (EBI) as an effective strategy to increase ART adherence and retention …
Baylor Role:
Collaborator
Recruiting
DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old (External Link)
This study will include 370 children and young people aged 2 to less than 15 years old who are living with HIV and are being treated with anti-HIV medicines for …
Baylor Role:
Collaborator
Completed
Targeting HIV Retention and Improved Viral Load Through Engagement ('THRIVE') (External Link)
Poor retention in HIV primary care results in lower rates of HIV viral suppression, higher rates of HIV transmission, and exacerbates racial and ethnic disparities in health outcomes, including survival. …
Baylor Role:
Lead Sponsor
Recruiting
Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV (External Link)
Although the prevalence of smoking has declined over the past 50 years, large disparities in tobacco use remain across several subgroups, particularly disadvantaged and health compromised populations. In fact, the …
Baylor Role:
Collaborator
Completed
VITAL Start: Brief Facility-based Video Intervention (External Link)
Universal HIV testing and treatment can accelerate population-level ART initiation and is critical to realize the UNAIDS 90-90-90 goals. Malawi pioneered Option B+ (B+), a novel application of test-and-treat that …
Baylor Role:
Lead Sponsor
Completed
Get Connected Efficacy Trial (External Link)
The number of HIV infections among men who have sex with men aged 15-24 (YMSM) has grown significantly in the past decade. For YMSM to successfully engage in HIV prevention …
Baylor Role:
Collaborator